Asked by: Charlie Dewhirst (Conservative - Bridlington and The Wolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will set out how the proposed modern service frameworks will interact with (a) National Institute for Health and Care Excellence guidance, (b) the proposed National Cancer Plan and (c) other health plans.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone in the National Health Service is responsible for delivering high-quality care. As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board will oversee the development of a new series of service frameworks.
Between 1997 and 2010, national service frameworks were a clinically led approach to developing guidance that supported sustained improvement in major condition outcomes, including by narrowing inequality and reducing unwarranted variation. As set out in the 10-Year Health Plan, we will reintroduce and modernise this approach. These modern service frameworks will define an aspirational, long-term outcome goal for a major condition and then identify the best evidenced interventions and the support for delivery.
Modern service frameworks will work with the National Institute for Health and Care Excellence and others to identify the best evidenced interventions that would support progress towards the outcome goal and set standards on how those interventions should be used.
Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions for future waves of modern service frameworks. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity.
Plans to introduce a modern service framework for cancer will be considered as part of the development of the National Cancer Plan.
Asked by: Lord Weir of Ballyholme (Democratic Unionist Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they have any plans to reform the NHS Health Check to identify individuals at increased risk for dementia.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Health Check programme, a core component of England’s cardiovascular disease (CVD) prevention programme, already aims to prevent some cases of dementia in eligible people by making them aware that many of the risk factors for CVD are the same as those for vascular dementia.
All attendees aged 65 to 74 years old should be made aware of the signs and symptoms of dementia and be signposted to memory services where appropriate.
Asked by: Jo White (Labour - Bassetlaw)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to develop a modern service framework for kidney disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board will oversee the development of a new series of service frameworks.
The modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the necessary support for delivery.
Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions for future waves of modern service frameworks. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity.
Asked by: Jo White (Labour - Bassetlaw)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of a modern service framework for kidney disease on improving outcomes for patients with chronic kidney disease who have received organ transplants.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board will oversee the development of a new series of service frameworks.
The modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the necessary support for delivery.
Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions for future waves of modern service frameworks. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity.
Asked by: Jo White (Labour - Bassetlaw)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the need for a Modern Service Framework for kidney disease to improve (a) earlier diagnosis, (b) care quality and (c) outcomes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board will oversee the development of a new series of service frameworks.
The modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the necessary support for delivery.
Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions for future waves of modern service frameworks. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to integrate multi-condition genetic risk scoring for high-impact conditions into the NHS prevention framework in order to achieve measurable reductions in disease prevalence and healthcare costs.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service, in partnership with Our Future Health, will trial the use of Integrated Risk Scores, which combine genomic, lifestyle, and health data, within the newly announced neighbourhood health services. Initially focused on cardiovascular disease and diabetes, the programme will expand to includes breast, bowel, and prostate cancer, with other diseases such as glaucoma, osteoporosis, and dementia under consideration. This marks a major step toward routine genetic testing in preventive care, enabling earlier and more personalised interventions.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what specific actions and policies they are considering to help families with genetic risk profiles across chronic conditions, such as type 1 and type 2 diabetes and cardiovascular disease, to be proactive in managing their conditions.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service, in partnership with Our Future Health, will trial the use of Integrated Risk Scores, which combine genomic, lifestyle, and health data, within the newly announced neighbourhood health services. Initially focused on cardiovascular disease and diabetes, the programme will expand to includes breast, bowel, and prostate cancer, with other diseases such as glaucoma, osteoporosis, and dementia under consideration. This marks a major step toward routine genetic testing in preventive care, enabling earlier and more personalised interventions.
Asked by: Charlie Dewhirst (Conservative - Bridlington and The Wolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to introduce a modern service framework for cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone in the National Health Service is responsible for delivering high-quality care. As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board will oversee the development of a new series of service frameworks.
Between 1997 and 2010, National Service Frameworks were a clinically-led approach to developing guidance that supported sustained improvement in major condition outcomes, including by narrowing inequality and reducing unwarranted variation. As set out in the 10-Year Health Plan, we will reintroduce and modernise this approach. These Modern Service Frameworks will define an aspirational, long-term outcome goal for a major condition and then identify the best evidenced interventions and the support for delivery.
Early priorities will include cardiovascular disease, severe mental illness and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions for future waves of Modern Service Frameworks. The criteria for determining other conditions for future Modern Service Frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity.
Plans to introduce a modern service framework for cancer will be considered as part of the development of the National Cancer Plan.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many yellow card reports of increased sexual arousal (Medical Dictionary for Regulatory Activities code 10021679) the Medicines and Healthcare products Regulatory Agency received each year since 2014, and what medications those reports were tied to.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
A total of 52 reports that describe increased sexual arousal suspected to be associated with the use of medicines or vaccines have been received through the Yellow Card scheme. The reports were received between 2014 and 2025 for a wide range of medicinal products which include antidepressants, hormonal medicines, vaccines, antipsychotics, antibiotics, cardiovascular medicines, drugs used to treat attention deficit hyperactivity disorder, sedatives, drugs used to treat dementia and diabetes, and single reports for drugs used to treat osteoporosis, Parkinson’s disease, and pain.
The term increased sexual arousal itself is not in the product information for any of the above classes of medicines, however terms such as increased libido and hypersexuality are reflected in product information for medicines used to treat Parkinson’s disease. The following table shows a breakdown of all spontaneous Yellow Card Reports the Medicines and Healthcare products Regulatory Agency (MHRA) received from 1 January 2014 to 4 November 2025, where the MedDRA, a categorisation of medical terminology, Lowest Level Term (LTT) ‘increased sexual arousal’ was reported:
Year | Number of reports |
2014 | 1 |
2015 | 1 |
2016 | 6 |
2017 | 4 |
2018 | 1 |
2019 | 4 |
2020 | 6 |
2021 | 14 |
2022 | 5 |
2023 | 4 |
2024 | 1 |
2025 | 5 |
of | 52 |
In addition, the following able shows a breakdown of all spontaneous Yellow Card Reports the MHRA received from 1 January 2014 to 4 November 2025 where the MedDRA LLT ‘increased sexual arousal’ was reported, broken down by substance:
Year | Substance | Number of reports |
2014 | TRAZODONE | 1 |
2015 | CITALOPRAM | 1 |
PROPRANOLOL | 1 | |
2016 | AMOXYCILLIN | 1 |
ARIPIPRAZOLE | 1 | |
CLAVULANIC ACID | 1 | |
ETHINYLESTRADIOL | 1 | |
FLUPENTHIXOL | 1 | |
METRONIDAZOLE | 1 | |
NORELGESTROMIN | 1 | |
SERTRALINE | 2 | |
SOLIFENACIN | 1 | |
2017 | CITALOPRAM | 2 |
MEMANTINE | 1 | |
SERTRALINE | 1 | |
2018 | SERTRALINE | 1 |
2019 | FLUOXETINE | 1 |
LISDEXAMFETAMINE | 1 | |
METHYLPHENIDATE | 1 | |
SERTRALINE | 1 | |
2020 | CANDESARTAN | 1 |
DULOXETINE | 1 | |
ETHINYLESTRADIOL | 1 | |
LEVONORGESTREL | 1 | |
LISINOPRIL | 1 | |
RISPERIDONE | 1 | |
TERIPARATIDE | 1 | |
ULIPRISTAL | 1 | |
VENLAFAXINE | 1 | |
2021 | ARIPIPRAZOLE | 1 |
ChAdOx1 nCoV-19 | 2 | |
CIPROFLOXACIN | 1 | |
CITALOPRAM | 2 | |
ESTRADIOL | 1 | |
FLUCLOXACILLIN | 1 | |
OESTRIOL | 1 | |
PAROXETINE | 1 | |
SERTRALINE | 2 | |
TOZINAMERAN | 2 | |
TRAZODONE | 1 | |
2022 | ARIPIPRAZOLE | 1 |
DONEPEZIL | 1 | |
ELASOMERAN | 1 | |
OESTRIOL | 1 | |
TOZINAMERAN | 1 | |
2023 | DIAZEPAM | 1 |
DOXYCYCLINE | 1 | |
LISDEXAMFETAMINE | 1 | |
MEMANTINE | 1 | |
2024 | CLONAZEPAM | 1 |
2025 | ARIPIPRAZOLE | 1 |
FLUOXETINE | 1 | |
LINAGLIPTIN | 1 | |
PRAMIPEXOLE | 1 | |
TIRZEPATIDE | 1 |
Asked by: Lord Weir of Ballyholme (Democratic Unionist Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to ensure that people with mild cognitive impairment or mild dementia are diagnosed early enough to benefit from novel treatments if approved by the National Institute for Health and Care Excellence in the future.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended in a NICE appraisal, usually within three months of final guidance.
A timely diagnosis is vital to ensuring that a person with dementia can access the advice, information, care, and support that can help them to live well and remain independent for as long as possible. We remain committed to recovering the dementia diagnosis rate to the national ambition of 66.7%. The latest dementia diagnosis rate reported by NHS England for the end of September 2025 was 66.3%.
To support commissioners and providers with appropriate data and to enable targeted support where needed, we have developed a memory service dashboard for management information purposes.
Our health system has struggled to support those with complex needs, including those with dementia. Under the 10-Year Health Plan, those living with dementia will benefit from improved care planning and better services.
We will deliver the first ever Modern Service Framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.